Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
13.77
-0.33 (-2.34%)
At close: Oct 29, 2025, 4:00 PM EDT
14.00
+0.23 (1.65%)
After-hours: Oct 29, 2025, 7:00 PM EDT
Takeda Pharmaceutical Revenue
Takeda Pharmaceutical had revenue of 1.11T JPY in the quarter ending June 30, 2025, a decrease of -8.39%. This brings the company's revenue in the last twelve months to 4.48T, up 1.52% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4.48T JPY
Revenue Growth
+1.52%
P/S Ratio
1.40
Revenue / Employee
94,410,410 JPY
Employees
47,455
Market Cap
43.50B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TAK News
- 7 days ago - Takeda Pharmaceutical Company Limited (TAK) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules Transcript - Seeking Alpha
- 7 days ago - China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion - WSJ
- 8 days ago - China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda - Reuters
- 8 days ago - Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market - PRNewsWire
- 8 days ago - Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Business Wire
- 15 days ago - US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership - Reuters
- 15 days ago - Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics - Business Wire
- 4 weeks ago - Takeda Pharmaceutical to exit cell therapy research - Reuters